研究结果启示,增加HDL胆固醇可能成为治疗动脉粥样硬化的途径。基于人胆固醇酰基转移蛋白(CETP)遗传缺陷的高HDL表型,发明了一类抑制CETP的新药。尽管CETP抑制剂torcetrapib能有效地促进HDL胆固醇增加,但是在最近一项大的临床试验中却失败了。辉瑞公司向FDA报告ILLUMINATE试验 The results suggest that increasing HDL cholesterol may be a therapeutic approach to atherosclerosis. Based on the high HDL phenotype of human cholesteryl acyltransferase (CETP) genetic defects, a new class of drugs that inhibit CETP has been invented. Although the CETP inhibitor torcetrapib is effective in boosting HDL cholesterol, it failed in a recent large clinical trial. Pfizer reports ILLUMINATE trial to FDA